159 related articles for article (PubMed ID: 37418056)
1. Does timing of neoadjuvant chemotherapy influence the prognosis in patients with early triple negative breast cancer?
Hatzipanagiotou ME; Pigerl M; Gerken M; Räpple S; Zeltner V; Hetterich M; Ugocsai P; Fernandez-Pacheco M; Inwald EC; Klinkhammer-Schalke M; Ortmann O; Seitz S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11941-11950. PubMed ID: 37418056
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer.
Hatzipanagiotou ME; Pigerl M; Gerken M; Räpple S; Zeltner V; Hetterich M; Ugocsai P; Inwald EC; Klinkhammer-Schalke M; Ortmann O; Seitz S
Breast Cancer Res Treat; 2024 Apr; 204(3):607-615. PubMed ID: 38238552
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Neoadjuvant
Philipovskiy A; Corral J; Dwivedi KA; Heydarian R; Gaur S
In Vivo; 2019; 33(4):1227-1234. PubMed ID: 31280213
[TBL] [Abstract][Full Text] [Related]
4. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases.
Xia LY; Hu QL; Zhang J; Xu WY; Li XS
World J Surg Oncol; 2020 Jun; 18(1):129. PubMed ID: 32539858
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis.
Bianco N; Palazzo A; Pagan E; Bagnardi V; Milano M; De Maio AP; Colleoni M
Breast; 2021 Oct; 59():351-357. PubMed ID: 34407499
[TBL] [Abstract][Full Text] [Related]
6. Utilization of neoadjuvant chemotherapy in high-risk, node-negative early breast cancer.
Prakash I; Neely NB; Thomas SM; Sammons S; Blitzblau RC; DiLalla GA; Hyslop T; Menendez CS; Plichta JK; Rosenberger LH; Fayanju OM; Hwang ES; Greenup RA
Cancer Med; 2022 Feb; 11(4):1099-1108. PubMed ID: 34989142
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysis.
Xiu M; Zhang P; Wang X; Fan Y; Li Q; Li Q; Wang J; Dong L; Luo Y; Yuan P; Ma F; Xu B
Int J Cancer; 2022 Aug; 151(4):578-589. PubMed ID: 35403702
[TBL] [Abstract][Full Text] [Related]
8. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients.
Sanford RA; Lei X; Barcenas CH; Mittendorf EA; Caudle AS; Valero V; Tripathy D; Giordano SH; Chavez-MacGregor M
Ann Surg Oncol; 2016 May; 23(5):1515-21. PubMed ID: 26678405
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.
Hall C; Karhade M; Laubacher B; Anderson A; Kuerer H; DeSynder S; Lucci A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S552-8. PubMed ID: 25968619
[TBL] [Abstract][Full Text] [Related]
10. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
11. Overall Survival Following Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Clinically Node Negative T1 Triple Negative Breast Cancer.
Huang K; Jakub J; Gabriel E; Moreno-Aspitia A; McLaughlin S
Ann Surg Oncol; 2023 Nov; 30(12):7026-7035. PubMed ID: 37490162
[TBL] [Abstract][Full Text] [Related]
12. TOPK: A new predictor of the therapeutic response to neoadjuvant chemotherapy and prognosis in triple-negative breast cancer.
Wang K; Chai J; Xu J; Wei J; Li P; Liu Y; Ma J; Xu T; Zhao D; Yu K; Fan L; Yan Q; Guo S; Li M; Wang Z
Pathol Res Pract; 2021 Oct; 226():153603. PubMed ID: 34500374
[TBL] [Abstract][Full Text] [Related]
13. [The influence of various myelosuppression degrees during neoadjuvant chemotherapy on the curative effect and prognosis of triple-negative breast cancer].
Niu YD; Zhang YW; Zhu RJ; Chu T; Wang L; Wang S; Li YY; Dong Y
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(29):2290-2294. PubMed ID: 35927061
[No Abstract] [Full Text] [Related]
14. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.
Fisher CS; Ma CX; Gillanders WE; Aft RL; Eberlein TJ; Gao F; Margenthaler JA
Ann Surg Oncol; 2012 Jan; 19(1):253-8. PubMed ID: 21725686
[TBL] [Abstract][Full Text] [Related]
15. Modified neoadjuvant clinicopathological risk stratification as a prognostic score in early and locally advanced triple-negative breast cancer.
Dubashi B; Matta K; Kayal S; Thumathy DB; Nisha Y; Dharanipragada K; Gunaseelan K; Ch Toi P; Ganesan P
J Cancer Res Ther; 2022; 18(1):168-172. PubMed ID: 35381779
[TBL] [Abstract][Full Text] [Related]
16. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
17. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
Gamucci T; Pizzuti L; Sperduti I; Mentuccia L; Vaccaro A; Moscetti L; Marchetti P; Carbognin L; Michelotti A; Iezzi L; Cassano A; Grassadonia A; Astone A; Botticelli A; Magnolfi E; Di Lauro L; Sergi D; Fuso P; Tinari N; Barba M; Maugeri-Saccà M; Landucci E; Conti F; Sanguineti G; De Tursi M; Iafrate G; Giordano A; Ciliberto G; Natoli C; Vici P
J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
[TBL] [Abstract][Full Text] [Related]
19. Dose-dense neoadjuvant chemotherapy in triple-negative breast cancer: Real-world data from a developing country.
Sharma RK; Gogia A; Deo S; Sharma D; Mathur S; Sagiraju HKR
Indian J Cancer; 2023 Oct; 60(4):505-511. PubMed ID: 38189648
[TBL] [Abstract][Full Text] [Related]
20. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Liedtke C; Mazouni C; Hess KR; André F; Tordai A; Mejia JA; Symmans WF; Gonzalez-Angulo AM; Hennessy B; Green M; Cristofanilli M; Hortobagyi GN; Pusztai L
J Clin Oncol; 2008 Mar; 26(8):1275-81. PubMed ID: 18250347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]